🇺🇸 FDA
Pipeline program

IPTACOPAN HYDROCHLORIDE, IPTACOPAN

CLNP023B12001B

Approved small_molecule active

Quick answer

IPTACOPAN HYDROCHLORIDE, IPTACOPAN for C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials